The emergence of ZIKV infection has prompted a global effort to develop safe and effective vaccines. We engineered a lipid nanoparticle (LNP) encapsulated modified mRNA vaccine encoding wild-type or variant ZIKV structural genes and tested immunogenicity and protection in mice. Two doses of modified mRNA LNPs encoding prM-E genes that produced virus-like particles resulted in high neutralizing antibody titers ($1/100,000) that protected against ZIKV infection and conferred sterilizing immunity. To offset a theoretical concern of ZIKV vaccines inducing antibodies that cross-react with the related dengue virus (DENV), we designed modified prM-E RNA encoding mutations destroying the conserved fusion-loop epitope in the E protein. This variant protected against ZIKV and diminished production of antibodies enhancing DENV infection in cells or mice. A modified mRNA vaccine can prevent ZIKV disease and be adapted to reduce the risk of sensitizing individuals to subsequent exposure to DENV, should this become a clinically relevant concern.
INTRODUCTION
Zika virus (ZIKV) was identified in 1947 from a Rhesus monkey in the Zika Forest of Uganda (Dick, 1952; Dick et al., 1952) . Historically, ZIKV circulated between Aedes species mosquitoes and non-human primates and episodically spilled into human populations in parts of Africa and Asia. Prior to 2010, ZIKV Infection was described as a self-limiting febrile illness with headache, rash, conjunctivitis, and myalgia. More recently, and especially in the context of its spread in the Western Hemisphere, more severe clinical consequences have been observed . Infection of fetuses during pregnancy has been associated with placental insufficiency and congenital malformations including cerebral calcifications, microcephaly, and miscarriage (Brasil et al., 2016; Rasmussen et al., 2016; van der Eijk et al., 2016) . In adults, ZIKV infection is linked to Guillain-Barré syndrome (GBS), an autoimmune disease characterized by paralysis and polyneuropathy Oehler et al., 2014) . Sexual transmission of ZIKV also has been described from men-to-women (Foy et al., 2011) , men-to-men (Deckard et al., 2016) , and women-to-men (Davidson et al., 2016) . Persistent ZIKV has been detected in semen, sperm, and vaginal secretions up to 6 months following infection (Mansuy et al., 2016; Murray et al., 2017) . ZIKV is now a global disease of the Americas, Africa, and Asia.
ZIKV is a member of the Flavivirus genus of the Flaviviridae family of enveloped RNA viruses. ZIKV has an $11 kb positive sense RNA genome. Translation of viral RNA in the cytoplasm generates a polyprotein that is cleaved into three structural proteins (capsid [C] , pre-membrane/membrane [prM/M], and envelope [E] ) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). ZIKV buds into the lumen of the endoplasmic reticulum as an immature virion composed of 60 icosahedrally arranged prM-E heterotrimers (Prasad et al., 2017) . As the virus transits through the secretory pathway, the acidic environment of the Golgi network triggers exposure of a furin protease cleavage site within prM. Cleavage of prM and release of the pr peptide in the extracellular space produces mature, infectious virions that display 90 antiparallel E homodimers on their surface. The ZIKV E protein is composed of three ectodomains (DI, DII, and DIII) and is the primary target of neutralizing antibodies. Potently inhibitory monoclonal antibodies (mAbs) against ZIKV target epitopes in all three E protein domains as well as quaternary structures composed of multiple domains within or across E dimers (Barba-Spaeth et al., 2016; (top) . An mRNA encoding the ZIKV prM/M and E structural genes was engineered (bottom). In this construct, prM is directed into the ER using a heterologous IgE signal sequence (IgE sig ) at the amino-terminus. (C) HeLa cells were transfected with prM-E mRNA, and SVPs in the supernatant were purified and concentrated by ultracentrifugation and then subjected to electron microscopy and negative staining. Low-and high-power images of purified SVPs are shown. Scale bar, 30 nm. One representative experiment of several is shown. (D) HeLa cell supernatants were collected for western blotting under non-reducing conditions with a mAb against the ZIKV E protein.
(E) Scheme of immunization of AG129 mice with one (prime) or two (prime-boost) doses of 2 or 10 mg with IgE sig prM-E or placebo mRNA LNP vaccines. (F-H) Serum was collected at 6 weeks after vaccination and analyzed for neutralization of ZIKV by PRNT assay. Representative curves are shown (F), and EC50 (G) and EC90 (H) values were calculated for individual animals in each group. Each point represents the mean of two independent experiments per animal. Data are a composite of two independent experiments with sera from each of the ten animals per group. EC50 and EC90 data were analyzed by a Kruskal-Wallis test with a multiple comparisons correction and compared to the placebo LNP vaccine (*p < 0.05; ***p < 0.001; ****p < 0.0001). The dashed lines indicate the limit of detection of the assay. Sapparapu et al., 2016; Stettler et al., 2016; Swanstrom et al., 2016; Wang et al., 2016; Zhao et al., 2016) . In addition to induction by infectious or inactivated virus particles, neutralizing antibodies against ZIKV can be produced after immunization with DNA plasmids encoding M-E protein or prM-E, which in some cases generates secreted virus-like subviral particles (SVPs) (Dowd et al., 2016b; Muthumani et al., 2016) .
The existence of two ZIKV lineages, African and Asian/American (Haddow et al., 2012) does not impact antibody neutralization substantively and thus, ZIKV is classified as a single serotype (Dowd et al., 2016a) . ZIKV is related to several pathogens that cause disease globally including dengue (DENV), yellow fever (YFV), West Nile (WNV), Japanese encephalitis (JEV), and tick-borne encephalitis (TBEV) viruses. Of these viruses, ZIKV is most closely related to the four serotypes of DENV as it shares 54 to 59% amino acid identity in the viral E protein .
Because of its potential to infect and cause harm to developing fetuses and neonates , there is an urgent call to develop countermeasures (Marston et al., 2016) . Several groups have developed subunit (prM-E or M-E DNA plasmid or adenovirus-vectored) or inactivated virus vaccine platforms capable of eliciting neutralizing antibodies that protect against ZIKV viremia in mice and non-human primates Dowd et al., 2016b; Larocca et al., 2016; Muthumani et al., 2016) . Some of these vaccine candidates have initiated or are scheduled to begin recruitment of subjects for evaluation in humans (NCT02840487, NCT02887482, NCT02809443, NCT02937233, NCT02952833, and NCT02963909).
The sequence similarity between ZIKV and DENV poses issues for vaccine development due to cross-reactivity of the human anti-ZIKV antibody response Sapparapu et al., 2016; Stettler et al., 2016) . Cross-reactive antibody responses may contribute minimally to protection, consistent with the limited neutralizing activity of many broadly-reactive anti-flavivirus mAbs in cell culture. Whereas primary infection with DENV generates an antibody response that protects against the homologous serotype, secondary infection with a heterologous DENV serotype can result in a potentially lethal shock syndrome. This disease is attributed in part to antibody-dependent enhancement of infection (ADE), whereby cross-reactive antibodies elicited by the first DENV serotype augment infection of the second DENV serotype in cells expressing Fc-g receptors (Morens, 1994) . This phenomenon could be relevant to ZIKV vaccination because DENV and ZIKV are related closely, and vaccinated subjects in or travelers to endemic areas could become exposed secondarily to DENV, which infects $390 million people per year (Bhatt et al., 2013) . Indeed, cross-reactive antibodies targeting the highly conserved fusion loop in DII of E (E-DII-FL) derived during natural ZIKV infection can augment infectivity of DENV in cell culture Kawiecki and Christofferson, 2016; Stettler et al., 2016) and in vivo in mice (Stettler et al., 2016) . These laboratory-based data are not conclusive, as epidemiological studies, which may take years to perform, are required to establish the impact of ZIKV humoral immunity on DENV pathogenesis. Vaccine strategies that reduce induction of cross-reactive antibodies might minimize the risk of sensitizing recipients to severe DENV infections, should the clinical relevance of ZIKV immunity on DENV pathogenesis be established.
We generated a versatile ZIKV vaccine platform in which lipid nanoparticles encapsulate modified mRNA encoding wild-type (WT) or variant ZIKV structural genes. Unlike DNA plasmid based vaccines, mRNA does not integrate into chromosomes, which can lead to insertional mutagenesis and potential oncogenesis (Pardi and Weissman, 2017 ). Non-amplifying or self-amplifying mRNA-based vaccines were used recently to generate humoral responses against influenza A virus in mice (Hekele et al., 2013; Petsch et al., 2012) or HIV in non-human primates (Bogers et al., 2015) . Our modified non self-amplifying mRNA vaccines have an optimized mRNA containing an open reading frame that encodes the antigen of interest, 5 0 and 3 0 untranslated regions that optimize translation efficiency and intracellular stability, and a proprietary nucleoside modification to minimize the indiscriminate activation of innate immunity. mRNA can stimulate innate immunity through Toll-like and RIG-I-like receptors (Desmet and Ishii, 2012; Karikó et al., 2004) . Although the adjuvant effect of stimulating innate immunity might be advantageous for protein vaccines, indiscriminate immune activation can inhibit mRNA translation, thus reducing antigen expression and immunogenicity of an mRNA vaccine (Clá udio et al., 2013; Coffman et al., 2010) . This can be overcome by replacing uridine nucleosides with naturally-occurring base modifications, such as pseudouridine and 5-methylcytidine (Anderson et al., 2011) . Here, a two-dose immunization of modified mRNA encoding ZIKV prM-E induced high levels of neutralizing antibodies that protected mice with genetic or acquired innate immune deficiencies against severe infection. Because mRNA vaccines can be synthesized with virtually any sequence, we created modified mRNA immunogens encoding mutations that abolished an immunodominant crossreactive epitope in E-DII-FL. These mRNA induced protective antibody responses against ZIKV in mice and minimized the generation of cross-reactive antibodies that enhanced DENV infection in cell culture and pathogenicity in mice.
RESULTS

An mRNA Vaccine Platform for ZIKV
We developed a vaccine platform for generating optimized lipid nanoparticles that encapsulate modified mRNA for intramuscular delivery to induce high levels of protein expression in vivo ( Figure 1A and Figure S1 ). As a proof-of-principle, we designed a modified mRNA encoding a type 1 (N7 m GpppG m ) cap, (I-J) AG129 Mice were challenged at 6 weeks post-vaccination with 10 4 PFU of ZIKV P6-740. Animals were monitored for survival (I) and weight loss (J). Error bars indicate standard error the mean (SEM). Survival data were analyzed by the log rank test (*p < 0.05; ***p < 0.001). Weight loss was analyzed by two-way ANOVA (***p < 0.001).
See also related Figures S1 and S2.
optimized 5 0 and 3 0 untranslated sequences (see STAR Methods), the signal sequence from human IgE, and the fulllength prM and E genes from an Asian (Mirconesia 2007) ZIKV strain (Lanciotti et al., 2008) , which has >99% amino acid sequence identity relative to strains from the Americas (Figure 1B) . The modified mRNA was synthesized enzymatically and packaged into lipid nanoparticles (LNPs). Incubation of LNPs containing IgE signal-prM-E mRNA (IgE sig -prM-E) with 293T or HeLa cells resulted in efficient expression and secretion of $30 nm SVPs, as judged by electron microscopy ( Figure 1C ), western blotting ( Figure 1D ) and mass spectrometry for ZIKV structural proteins in the cell supernatants (data not shown).
Vaccine Efficacy in AG129 Mice
We first assessed the immunogenicity and protective activity of IgE sig -prM-E LNPs in immunocompromised mice lacking type I and II interferon (IFN) signaling responses. Eight-week-old Ifnar1 À/À Ifngr À/À AG129 male and female mice were divided into five groups, which received an intramuscular inoculation of 2 or 10 mg of IgE sig -prM-E LNPs or 10 mg of a non-translating RNA LNP. Groups 1, 3, and 5 were boosted with the same dose at 21 days after vaccination whereas Groups 2 and 4 were not boosted ( Figure 1E ). At day 42 after immunization, mice were phlebotomized for serum neutralizing antibody analysis ( Figures 1F-1H and Figure S2 ). Mice receiving the IgE sigprM-E LNPs with a boost had the strongest serum neutralizing response against ZIKV, with reciprocal dilution EC50 (halfmaximal inhibition of virus infection) and EC90 values of up to 1/10,000 and 1/1,000, respectively. Mice receiving only a single immunization had lower neutralizing titers. At 42 days after vaccination, AG129 mice were challenged with the ZIKV strain P6-740 (Malaysia, 1966) . As expected (Aliota et al., 2016) , AG129 mice receiving the negative control LNP vaccine succumbed to ZIKV infection ( Figure 1I ). With the exception of a single animal, recipients of the 2 or 10 mg IgE sig -prM-E LNP vaccine with a boost as well as those receiving a single 10 mg dose all survived infection. In comparison, mice receiving a single 2 mg dose of the vaccine displayed an intermediate phenotype with a 60% survival rate. Weight measurements correlated with lethality, as mice receiving the IgE sig -prM-E LNP vaccine were protected, whereas the negative controls lost weight beginning at approximately day 10 after challenge ( Figure 1J ).
Vaccine Efficacy in C57BL/6 Mice
To test the immunogenicity and efficacy of the IgE sig -prM-E LNP vaccine efficacy in an immunocompetent mouse strain, we inoculated via intramuscular injection 8-week-old male C57BL/6 WT mice with 10 mg of IgE sig -prM-E LNPs. These animals were phlebotomized prior to a single boost at day 28 (4 weeks) and before challenge at either day 56 (8 weeks) or day 126 (18 weeks). As expected, serum neutralization titers were relatively low prior to boosting; however, titers peaked at 4 weeks after boosting (EC50 of 1/10,000) and remained elevated 18 weeks post-initial vaccination ( Figures 2A-2C and Figure S3 ). To create a lethal challenge model, we passively transferred 2 mg of a blocking anti-ifnar1 antibody 1 day prior to infection with 10 6 focus-forming units (FFU) of a mouse-adapted African ZIKV strain (Dakar 41519) (Sapparapu et al., 2016; Zhao et al., 2016) . All mice immunized with IgE sig -prM-E LNPs were protected against lethal ZIKV infection compared to the control group, which had a 30% survival rate ( Figure 2D ). Mice vaccinated with IgE sig -prM-E mRNA LNPs did not display any loss in weight ( Figure 2E ) nor had measurable viremia in serum at 5 days after challenge ( Figure 2F ).
Modified Vaccines Lacking the Immunodominant E-DII-FL Epitope Generate a Protective Anti-ZIKV Response
The highly conserved FL epitope in DII of the flavivirus E protein is immunodominant in humans (Beltramello et al., 2010; Crill et al., 2007; Dejnirattisai et al., 2010; Oliphant et al., 2007; Sapparapu et al., 2016; Stettler et al., 2016) . As such, infection with ZIKV or vaccination with ZIKV structural proteins could induce cross-reactive antibodies, which might enhance DENV infection and disease through ADE (Morens, 1994; Stettler et al., 2016) . To minimize this possibility, we generated modified mRNA vaccines by engineering four mutations (T76R, Q77E, W101R, and L107R) in or near the E-DII-FL (prM-E-FL) that abolish antibody reactivity of FL-specific antibodies (Chabierski et al., 2014; Crill et al., 2012; Oliphant et al., 2007) . We also generated a separate series of mRNA LNPs by replacing the IgE leader sequence with one from Japanese encephalitis virus (JEV sig ), a feature included in other flavivirus prM-E DNA vaccines to increase the efficiency of host signalase cleavage (Davis et al., 2001; Dowd et al., 2016b) , and by further optimizing codon usage ( Figure 3A ). Western blotting analysis showed similar levels of SVP expression in HeLa cell supernatants after transfection of WT and FL mutant mRNA, and a loss of FL reactivity was confirmed for the prM-E-FL mRNA by an absence of binding of a mAb (WNV E60) that recognizes this epitope (Oliphant et al., 2006) (Figure 3B ).
Immunocompetent 8-week-old female BALB/c mice were immunized with 2 mg or 10 mg of IgE sig -prM-E or JEV sig -prM-E (WT or FL mutant) LNPs and boosted with the same LNPs 4 weeks later. At 8 weeks after initial vaccination, serum was analyzed for neutralizing activity using ZIKV reporter virus particles (RVPs) (Dowd et al., 2016a) (Figure 3 and Figure S4 ). Mice receiving 2 or 10 mg doses of the IgE sig -prM-E WT and FL mutant LNPs showed similar neutralization titers ( Figure 3C ), with EC50 values of $1/5,000 ( Figure 3E ). The 2 and 10 mg dose of the WT JEV sig -prM-E LNPs induced stronger inhibitory responses with EC50 values of $1/100,000 (Figures 3D and 3E) and EC90 values of $1/10,000 ( Figure 3F ). The mutant JEV sig -prM-E-FL LNPs, however, induced antibody responses with lower EC50 and EC90 values, which still approached 1/10,000 and 1/500, respectively.
At $13 weeks after initial vaccination, mice were challenged with ZIKV Dakar 41519 after pre-administration of anti-ifnar1 blocking antibody. At day 3 after infection, serum was analyzed for viremia. Consistent with their high neutralizing titers, all mice immunized with 2 or 10 mg doses of JEV sig -prM-E LNPs lacked measurable viremia ( Figure 3G ). All other vaccine groups (IgE sigprM-E LNPs (WT or FL) or JEV sig -prM-E FL LNPs) had breakthrough viremia in some animals, although levels were 10-to 100-fold lower than observed with placebo LNPs. Mice were euthanized at day 7 after infection and spleen, uterus, and brain were analyzed for ZIKV RNA levels ( Figures 3H-3J ). Most mice vaccinated with prM-E LNPs showed markedly reduced levels of viral RNA in the spleen (>100-fold) and virtually no detectable viral RNA in the uterus or brain, whereas the placebo immunized animals had mean levels of 10 5 to 10 6 FFU equivalents per gram of tissue. Mice vaccinated with the 2 mg dose of IgE sig -prM-E FL or JEV sig -prM-E FL LNPs showed slightly less protection, as viral RNA was detectable in some animals in the spleen and brain, albeit at much lower levels than those immunized with placebo LNPs.
To establish an immune correlate of complete protection against ZIKV in this model, we compared the EC50 values from all mRNA LNP vaccines with the levels of viral RNA recovered in the serum and spleen from individual mice. This analysis revealed an expected inverse relationship between neutralizing titers and levels of ZIKV RNA in serum and tissues and defined a cut-off EC50 value of $1/10,000 to completely prevent viremia and tissue dissemination ( Figures 3K and 3L) . We next evaluated whether the JEV sig -prM-E mRNA LNP vaccines, which protected almost completely against viremia or infection in tissues, conferred sterilizing immunity. The vast majority of animals (80% to 90%) receiving 2 or 10 mg doses of the JEV sig -prM-E mRNA vaccines failed to boost neutralizing titers one week after challenge with infectious ZIKV, consistent with sterilizing immunity ( Figure 3M ). In comparison, most animals (82%-100%) showing breakthrough viremia or tissue burden with the IgE sigprM-E or JEV sig -prM-E FL mRNA vaccines sustained marked increases in EC50 and EC90 values after challenge ( Figure 3N ), consistent with the induction of an anamnestic response.
Mutation of the DII-Fusion Loop Epitope Diminishes ADE in Cells and Mice
To evaluate whether the FL mutant vaccines diminished induction of cross-reactive enhancing antibodies, we incubated dilutions of serum obtained at 8 weeks after immunization with (B and C) EC50 (B) and EC90 (C) values were calculated for individual animals in each group. The dashed lines indicate the limit of detection of the assay. Data were analyzed using the Mann-Whitney test and compared to the placebo LNP vaccine at each time point (**p < 0.01; ***p < 0.001; n.s. indicates not significant). (D-F) At week 8 or 18, vaccinated C57BL/6 mice were administered 2 mg of anti-ifnar1 blocking antibody and 1 day later challenged with 10 5 FFU of mouse adapted ZIKV Dakar 41519. Animals were monitored for survival (D) and weight loss (E). At day 5 after viral challenge, serum was analyzed for levels of ZIKV RNA (F). The dashed line indicates the limit of detection of the assay. Survival data were analyzed by the log rank test (***p < 0.001). Weight loss was analyzed by twoway ANOVA (***p < 0.001) for surviving animals; arrows indicate days having statistically significant differences from placebo vaccine. Viremia data were analyzed by a Mann-Whitney test (*p < 0.05; ***p < 0.001). See also related Figure S3 .
(legend on next page)
DENV serotype 1 (DENV-1) RVPs (Dowd et al., 2015) and assessed infection in K562 cells, which express the activating human Fc-g receptor IIA (CD32A). Whereas sera from mice vaccinated with WT IgE sig -prM-E or JEV sig -prM-E mRNA LNPs all showed bell-shaped, canonical antibody enhancement curves, many of the sera from mice immunized with serum from IgE sigprM-E-FL or JEV sig -prM-E-FL LNPs supported enhancement at only high concentrations and with considerably reduced efficiency ( Figures 4A-4C and Figure S5 ). Indeed, the peak serum enhancement titer (PET [Boonnak et al., 2008] ) was $100-fold lower in mice immunized with mutant forms of the fusion loop ( Figure 4D ). A similar reduction in enhancing power, or the fraction of infected cells at the PET was observed ( Figures 4A, B , and 4E). Thus, introduction of mutations in the FL of ZIKV E reduced the production of enhancing antibodies against DENV, as judged by cell culture assays.
To determine the physiological significance of these results, we used an established passive transfer model of ADE for DENV in AG129 mice (Balsitis et al., 2010; Zellweger et al., 2010) with serum from the IgE sig -prM-E and IgE sig -prM-E-FL or JEV sigprM-E and JEV sig -prM-E-FL vaccinated mice. We first evaluated the relative neutralizing activity of DENV-2 of pooled ZIKV serum using an established RVP assay in Raji-DCSIGNR cells (Dowd et al., 2015) . Consistent with studies using FL-specific mAbs (Williams et al., 2013) , the pooled sera from IgE sig -prM-E or or JEV sigprM-E but not IgE sig -prM-E-FL or JEV sig -prM-E-FL vaccinated animals inhibited DENV-2 infection in cell culture ( Figure 4F and Figure S6A ), indicating a cross-reactive antibody (likely FL-specific) was produced only in mice receiving the WT but not FL mutant vaccines, and this antibody could neutralize infection in Raji-DCSIGNR cells lacking activating Fc-g receptors. We next transferred pooled sera to AG129 mice 1 day prior to challenge with a non-lethal dose of DENV-2. Whereas administration of 1 or 10 mL of serum from mice vaccinated with WT IgE sig -prM-E or JEV sig -prM-E LNPs or a positive control anti-prM mAb (2H2) resulted in uniformly lethal infection and severe disease due to antibody enhancement, transfer of equivalent amounts of sera from mice vaccinated with IgE sig -prM-E FL or JEV sig -prM-E-FL mutant LNPs resulted in significantly less morbidity and mortality ( Figure 4G and 4H and Figure S6B ).
DISCUSSION
As ZIKV emerges, the urgency for development and deployment of counter-measures to control infection increases (Marston et al., 2016) . Here, we developed a ZIKV vaccine platform with modified mRNA encoding the prM-E proteins that was packaged into LNPs. Although mRNA-based vaccines were used recently to generate humoral responses against influenza A virus in mice (Hekele et al., 2013; Petsch et al., 2012) or HIV in non-human primates (Bogers et al., 2015) , these platforms differed from ours in their use of self-replicating RNA or protamine complexed mRNA. We selected LNPs for delivery of the modified mRNA as they have been validated in clinical trials for siRNA delivery and are well tolerated compared to other non-viral delivery systems (Coelho et al., 2013) . In proof-of-principle studies, we showed that LNP-delivered modified mRNA induced neutralizing antibodies that protected several strains (129 Sv, BALB/c, or C57BL/6) of susceptible mice with genetic or acquired deficiencies in IFN signaling against lethal ZIKV challenge. The neutralization titers induced by the IgE sigprM-E mRNA LNPs were uniformly high (50% neutralization titer of $1/10,000) in all three mouse models. The protective responses conferred by mRNA LNP vaccines were durable; even 14 weeks after boosting, challenged mice showed no morbidity or mortality. Furthermore, by further optimizing the prM signal sequence and codon usage (JEV sig -prM-E), we induced even more potent responses (EC50 of $1/100,000 and EC90 of ) immediately before (Pre) or 7 days after (Post) ZIKV challenge and analyzed for neutralizing activity using ZIKV RVPs. EC50 and EC90 values were analyzed for differences by a paired t test (n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001). Indicated at the bottom of the graphs are the number of animals showing a 4-fold increase in neutralization titer (positive anamnestic response) at 7 days after ZIKV challenge. See also related Figure S4 .
1/10,000) that resulted in sterilizing immunity in the majority of mice. The basis for the enhanced immunogenicity of the JEV sigprM-E versus IgE sig -prM-E mRNA remains uncertain at this time.
While other candidate ZIKV vaccines have demonstrated protection in mice against ZIKV viremia with IgG titers of $1/2,000 , some of these studies used (G and H) Enhancing effects of ZIKV immune serum on DENV-2 infection in AG129 mice. Recipient AG129 mice were passively transferred PBS, 1 mL (G) or 10 mL (H) of pooled serum from BALB/c mice vaccinated with WT or FL mutant IgE sig -prM E LNPs, or 15 mg of anti-prM mAb (2H2, positive control). One day later, animals were challenged with 10 5 FFU of DENV-2 (strain S221) and followed for mortality (left) and clinical score (right) (1 (healthy) to 7 (deceased) scale; see STAR Methods). Results are pooled from two to three independent challenge experiments (numbers of animals indicated beneath graph) with the exception of the antiprM mAb, which was administered in only one of the two experiments as a positive control. Survival curves between serum transfers from IgE sig -prM-E (WT and FL mutant LNPs) vaccinated mice were statistically different (****p < 0.0001, log-rank test). See also related Figures S5 and S6. immunocompetent strains for challenge, which do not support as efficient ZIKV infection due to a species-specific lack of antagonism of IFN signaling (Grant et al., 2016; Kumar et al., 2016; . Passive transfer and challenge studies in non-human primates with DNA plasmid or inactivated vaccines suggested that a neutralization titer of 1/100 (measured by microneutralization assay) or 1/1,000 (measured by RVP assay) is required to prevent viremia in the majority of ZIKV-infected animals Dowd et al., 2016b) . However, no prior study assessed sterilizing immunity, as judged by the combined absence of virus in target tissues and lack of evidence of an anamnestic humoral response. For vaccine development, a key question remains as to correlates of vaccine protection in pregnancy and whether sterilizing immunity will be required to prevent seeding of the placenta and fetal infection and injury. In antiifnar1-treated susceptible mice, the level of neutralizing antibodies required for conferring sterilizing immunity was substantially higher (> 100 to 1,000-fold) than required to reduce viral burden or confer survival protection. Vaccination studies in pregnant animals are planned to establish the correlate of immune protection that completely prevents maternal-fetal transmission.
Because of the versatility of the platform, we engineered additional mRNA LNP vaccines with mutations in the conserved E-DII-FL, which abolish reactivity of monoclonal and polyclonal antibodies targeting this region (Chabierski et al., 2014; Crill et al., 2012; Hughes et al., 2012; Vogt et al., 2011) . The FL mutant mRNA vaccines induced neutralizing antibody responses in nonpregnant female BALB/c mice that protected against virus dissemination to the uterus and brain. Moreover, the FL mutant ZIKV vaccines induced serum antibody responses that resulted in less ADE of DENV-1 infection in cell culture and immune enhancement of DENV-2 infection in AG129 mice. Our results are analogous to a prior study with a DENV-1 DNA plasmid vaccine in which the FL epitope was altered by introducing G106R and L107D mutations ; in that study, mice immunized with cross-reactivity-reduced monovalent DENV-1 DNA vaccines had diminished immune enhancement of DENV-2 infection in mice. Although our FL mutant mRNA LNP vaccines minimized ADE, we did observe a reduction in neutralizing titer ($7-fold decrease in EC50) for JEV sig -prM-E FL LNPs compared to the respective WT LNPs; however, no significant difference in neutralization was observed between IgE sig -prM-E WT and FL mutant vaccines. Although further studies are warranted, mRNA LNPs with FL mutations may induce lower neutralizing responses because (a) they produce SVPs that are less stable; (b) the absence of the FL results in a change in the display of neutralizing epitopes; or (c) the mutation of the FL in ZIKV SVPs prevents induction of neutralizing antibodies that bind epitopes proximal to the FL, as observed with EDE antibodies Dejnirattisai et al., 2016) . Thus, there is a trade-off for using the FL mutant LNPs; although cross-reactivity and ADE of DENV infection is reduced, neutralizing activity and the likelihood of conferring sterilizing immunity also are reduced. Second generation crossreactivity reduced constructs with a different array of mutations in conserved regions may prove even more immunogenic.
Our mRNA LNP ZIKV vaccine platform adds to a burgeoning pipeline that focuses on subunit-based or inactivated virion approaches. Three groups reported DNA plasmid vaccines encoding ZIKV M-E or prM-E genes that induced neutralizing antibodies in mice and non-human primates and protected against viremia or lethal virus challenge Dowd et al., 2016b; Larocca et al., 2016; Muthumani et al., 2016) . A rhesus adenovirus-vectored vaccine encoding ZIKV M-E genes induced neutralizing antibodies after a single dose in four rhesus macaques . Immunization of BALB/c mice or rhesus macaques with an alum-adjuvanted chemically inactivated ZIKV vaccine induced neutralizing antibodies and cellular immunity after two doses and protected against plasma viremia, or viral RNA in urine, cerebrospinal fluid, colorectal, and cervicovaginal secretions . A human adenovirus vectored vaccine producing soluble E protein trimers induced neutralizing antibodies and protected 1-weekold mice from ZIKV challenge . Although all of these vaccine platforms show promise, none have been evaluated for induction of cross-reactive antibodies that in theory, could enhance DENV infection and disease. Nonetheless, it remains to be established whether the enhancement of DENV infection and disease, which can be demonstrated in vitro and in mice, becomes a clinically relevant concern for ZIKV vaccines. In the absence of epidemiological proof, it may be difficult to justify the evaluation of cross-reactivity reduced variant vaccines in humans, in view of the decreased immunogenicity, especially when compared to the extraordinarily strong response generated with our WT JEV sig -prM-E construct. Nonetheless, the modified mRNA platform is well-positioned to respond rapidly to emerging epidemiology data.
In summary, we describe the generation of a ZIKV vaccine, utilizing modified mRNA encapsulated into LNPs that can be easily manipulated to optimize neutralization capacity and limit potentially undesired cross-reactivity. Our JEV sig -prM-E mRNA LNPs induced remarkable neutralizing titers that in most animals conferred sterilizing immunity. Consistent with our results, a recent study also reported the utility of LNP-encapsulated mRNA encoding the prM and E genes as a candidate vaccine for ZIKV infection . The flexibility of this platform allows for the future inclusion of additional mRNA encoding other flavivirus proteins (e.g., NS1) that could augment protective responses (Costa et al., 2007; Costa et al., 2006) or immunodominant helper CD4 T cell epitopes (Hung et al., 2007) . Future studies will be directed on evaluating the immunogenicity and protective efficacy of these mRNA vaccines in pregnant mice, non-human primates, and ultimately, humans.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Mouse experiments BALB/c and C57BL/6 mice were purchased from The Jackson Laboratory, and AG129 mice were bred in the animal facilities at Utah State University, Washington University, or the La Jolla Institute for Allergy and Immunology. All mice were housed in pathogen-free mouse facilities. For immunizations, mice were inoculated via an intramuscular route with 50 mL of the indicated vaccine LNP constructs. For challenge studies, mice were inoculated subcutaneously with 10 4 PFU of ZIKV P6-740 or 10 6 FFU of mouse-adapted ZIKV Dakar 41519 in 50 mL of HBSS + 0.1% FBS. For ZIKV challenge studies in BALB/c and C57BL/6 mice, 2 mg of anti-iFNAR1 blocking antibody (MAR1-5A3; Sheehan et al., 2006) was administered via intraperitoneal injection 24 hr prior to viral infection. For DENV challenge studies in AG129 mice, animals were passively transferred pooled vaccine immune sera or PBS 1 day prior to infection with $10 5 or 10 4 FFU of DENV-2 S221 or DENV-2 D2S20. Animals were monitored for mortality and clinical score (1 = heathy; 2 = slightly ruffled fur; 3 = very ruffled fur; 4 = mild lethargy, decreased scurrying activity; 5 = very sick, slow to no movement; 6 = very sick, euthanize (in distress); 7 = deceased) as described previously (Tang et al., 2016) .
METHOD DETAILS
Viruses and cells ZIKV strain Dakar 41519 (Senegal, 1984) and P6-740 (Malaysia, 1966) were provided by the World Reference Center for Emerging Viruses and Arboviruses (R. Tesh and S. Weaver, University of Texas Medical Branch). To create a mouse-adapted more pathogenic variant of ZIKV Dakar 41519, it was passaged twice in Rag1 À/À mice (Sapparapu et al., 2016; Zhao et al., 2016) . ZIKV strain Paraiba 2015 (Brazil) was provided by S. Whitehead (NIH, Bethesda, MD) (Tsetsarkin et al., 2016) . DENV-2 strain S221 is a mouse-adapted strain that has been described previously (Yauch et al., 2009) . Virus stocks were propagated in mycoplasma-free Vero cells and titrated by focus-forming assay (FFA), as described previously . Experiments with ZIKV and DENV were conducted under biosafety level 2 (BSL2) containment at Washington University School of Medicine or under BSL3 containment at Utah State University with Institutional Biosafety Committee approval.
Generation of modified mRNA and LNP
The mRNA was synthesized in vitro using T7 polymerase-mediated DNA-dependent RNA transcription where the UTP was substituted with 1-methylpseudoUTP, using a linearized DNA template, which incorporates 5 0 and 3 0 untranslated regions (UTRs) and includes a poly-A tail (5 0 -UTR: GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC; and 3 0 -UTR: UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCC GUACCCCCGUGGUCUUUGAAUAAAGUCUGA). A donor methyl group S-adenosylmethionine (SAM) was added to the methylated capped RNA (cap 0), resulting in a cap 1 structure to increase mRNA translation efficiency. The modified mRNAs encoded the signal sequences from human IgE (MDWTWILFLVAAATRVHS) or JEV prM (MWLVSLAIVTACAGA) and the prM and E genes from an Asian ZIKV strain (Micronesia 2007, GenBank accession number EU545988; Lanciotti et al., 2008) , which is > 99% identical to circulating American strains.
LNP formulations were prepared using a modified procedure of a method described for siRNA . Briefly, lipids were dissolved in ethanol at molar ratios of 50:10:38.5:1.5 (ionizable lipid: DSPC: cholesterol: PEG-lipid). The lipid mixture was combined with a 50 mm citrate buffer (pH 4.0) containing mRNA at a ratio of 3:1 (aqueous:ethanol) using a microfluidic mixer (Precision Nanosystems, Vancouver, BC). Formulations were dialyzed against PBS (pH 7.4) in dialysis cassettes for at least 18 hr. Formulations were concentrated using Amicon Ultra Centrifugal Filters (EMD Millipore, Billerica, MA), passed through a 0.22-mm filter and stored at 4 C until use. All formulations were tested for particle size, RNA encapsulation, and endotoxin and were found to be between 80 to 100 nm in size, with greater than 90% encapsulation and < 1 EU/ml of endotoxin.
Viral protein analysis
SVPs were floated on a 10%-50% sucrose gradient (50 mM MES pH 5.5, 120 mM NaCl) and ultracentrifuged at 32,000 rpm at 4 C for 4 hr in a Beckman SW55 rotor. Fractions (1 ml) were collected and pelleted by a second ultracentrifugation step over a 20% sucrose cushion at 32,000 rpm at 4 C for 2 hr. Protein concentration of SVPs was measured using a spectrophotometer (280 nm wavelength). Western blotting was performed using NuPAGE MES western blot system (Thermo Fisher) reagents as per the manufacturer's instructions. Samples were boiled at 100 C for 10 min in the absence of reducing agent. Samples (100 or 500 ng total protein) were loaded on 4%-12% NuPAGE gradient gel and electrophoresed. Proteins were transferred onto nitrocellulose membranes using an iBlot 2 gel transfer system. Membranes were washed three times with deionized water and blocked in PBS with 5% Blotto (Thermo Fisher) overnight at 4 C. Primary mAbs (WNV E60 [Oliphant et al., 2006] or mouse anti-ZIKV E [Biofront, BF-1176-86] ) were added at 1 mg/ml in PBS supplemented with 5% Blotto and 0.2% (v/v) Tween 20 (Sigma) and incubated for 2 hr at room temperature with agitation. Membranes were washed three times with PBS supplemented with 0.2% Tween 20. Secondary antibody (horseradish peroxidase conjugated goat anti-mouse IgG [Ab97023, Abcam]) was added at 0.25 mg/ml in PBS supplemented with 5% Blotto and 0.2% Tween 20 for 2 hr at room temperature with agitation. After final washing, blots were developed using Amersham ECL prime solution (GE Healthcare Life Sciences) for 2 min and imaged. SeeBlue plus2 (Invitrogen) pre-stained protein ladders were included for molecular weight references.
To compare expression of SVPs from different mRNA vaccine constructs, HeLa cells were transfected with 1.25 mg of mRNA constructs using Lipofectamine 2000 (Thermo Fisher), and cells were harvested 24 hr later. Cell lysates were prepared in RIPA lysis buffer (Thermo Fisher) with phosphatase and protease inhibitors (Millipore) added.
Electron microscopy of SVPs
The SVPs were imaged by electron microscopy and negative staining using a fee-for-service facility (University of California, Los Angeles). Briefly, purified SVPs (2.5 ml) were applied to a Glow-discharge carbon-coated grid (Ted Pella Inc.). Staining (2% uranyl acetate) was added in a drop-wise manner for 60 s. After blotting of excess liquid and drying, the images were collected on a FEI Tecnai TF20 transmission electron microscope at an accelerating voltage of 200 kV using TVIPS EM-Menu program. The nominal magnifications used were 50,000, 29,000 and 14,500 with 2 binning.
Measurement of viral burden
At specified time points after ZIKV challenge, blood was collected and organs were recovered. Organs were weighed and homogenized using a bead-beater apparatus (MagNA Lyser, Roche), and serum was prepared after coagulation and centrifugation. Tissue samples and serum from ZIKV-infected mice were extracted with the RNeasy Mini Kit (QIAGEN). ZIKV RNA levels were determined by TaqMan one-step quantitative reverse transcriptase PCR (qRT-PCR) on an ABI 7500 Fast Instrument using standard cycling conditions. Viral burden is expressed on a log 10 scale as viral RNA equivalents per gram or per milliliter after comparison with a standard curve produced using serial 5-fold dilutions of ZIKV RNA from known quantities of infectious virus. For ZIKV, the following primer sets were used: 1183F: 5 0 -CCACCAATGTTCTCTTGCAGACATATTG-3 0 ; 1268R: 5 0 -TTCGGACAGCCGTTGTCCAACACAAG-3 0 ; and probes (1213F): 5 0 -56-FAM/AGCCTACCTTGACAAGCAGTC/3IABkFQ-3 0 .
Neutralization assays (a) PRNT or FRNT assays. Serial dilutions of heat-inactivated sera obtained from AG129 or C57BL/6 mice were incubated with 50 to 100 FFU of ZIKV (Paraiba, Brazil 2015) for 1 hr at 37 C. The serum Ab-virus complexes were added to Vero cell monolayers in 96-well plates for 60 min at 37 C. Plaque assays were performed as described previously (Brien et al., 2013; For FRNT assays, cells were overlaid with 1% (w/v) methylcellulose in MEM supplemented with 4% heat-inactivated FBS. Plates were fixed 40 hr later with 1% PFA in PBS for 1 hr at room temperature. The plates were incubated sequentially with 500 ng/ml of humanized anti-WNV E60 (Oliphant et al.) and horseradish-peroxidase-conjugated goat anti-human IgG in PBS supplemented with 0.1% (w/v) saponin (Sigma) and 0.1% BSA. ZIKV-infected cell foci were visualized using TrueBlue peroxidase substrate (KPL) and quantitated on an ImmunoSpot 5.0.37 macroanalyzer (Cellular Technologies). (b) RVP assays. RVPs incorporating the structural proteins of ZIKV or DENV were produced by complementation of a previously described sub-genomic GFP-expressing replicon derived from a lineage II strain of WNV (Dowd et al., 2016a; Dowd et al., 2015) . Serial dilutions of heat-inactivated sera obtained from BALB/c mice were mixed with ZIKV (strain H/PF/2013; French Polynesia, 2013) or DENV-2 (strain 16681) reporter viral particles (RVPs) and incubated for 1 hr at 37 C. Immune complexes were added in duplicate technical replicates to pre-plated Vero cells in a 96-well plate and incubated for 2 days. Cells were trypsinized, resuspended in 4% PFA in PBS, and RVP infection scored as a function of GFP expression by flow cytometry. All neutralization data were analyzed by non-linear regression to determine the dilution of sera required to inhibit 50% (EC50) and 90% (EC90) of infection. RVP studies were performed starting at an initial serum dilution of 1:100 (based on the final volume of cells, virus, and sera per well), which was designated as the limit of detection.
ADE assays
Serial dilutions of heat-inactivated sera obtained from BALB/c mice were mixed with DENV-1 RVPs (Western Pacific-74 strain) and incubated for 1 hr at 37 C. Immune complexes were added in duplicate technical replicates to K562 cells that express the Fc-g receptor CD32A and incubated for 2 days. Due to limited volumes of sera, a small number of samples (four) could not be performed in duplicate. Cells were fixed with 2% PFA, and RVP infection was scored as a function of GFP expression by flow cytometry. To normalize the magnitude of enhancement across independent experiments, results are displayed relative to the maximum infectivity observed with a control cross-reactive WNV mAb E60 (Oliphant et al., 2006 ) run in parallel. ADE studies were performed starting at an initial serum dilution of 1:60 (based on the final volume of cells, virus, and sera per well), which was designated as the limit of detection. For calculations of peak enhancing titer, samples for which no enhancement (infectivity) was observed are reported as a titer of 30 (one half the limit of detection).
QUANTIFICATION AND STATISTICAL ANALYSIS
All data were analyzed with GraphPad Prism software. Kaplan-Meier survival curves were analyzed by the log rank test, and weight losses were compared using two-way ANOVA. For neutralization antibody titers and viral burden analysis, the log titers and levels of viral RNA were analyzed by a Kruskal-Wallis 2-way ANOVA with a multiple comparisons correction. A p value of < 0.05 indicated statistically significant differences.
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